{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:12:50Z","timestamp":1793351570139,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.semerg.2024.102418","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T13:01:38Z","timestamp":1737205298000},"page":"102418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Triple inhaled therapy of formoterol\/glycopyrrolate\/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions"],"prefix":"10.1016","volume":"51","author":[{"given":"A.","family":"Calder\u00f3n-Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Miguel Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de Sim\u00f3n Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Campos T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Chac\u00f3n Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Alonso Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gonz\u00e1lez Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Montero Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Escribano Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Calderon Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de Miguel D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"de Sim\u00f3n Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Campos T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Alonso Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Tenes May\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Chac\u00f3n Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Gonz\u00e1lez Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Montero Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Escribano Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pilar Javierre Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cuevas Cortijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Rodriguez Reguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Coleto Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Jim\u00e9nez Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"De Miguel Gordillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Bermejo Barbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"F\u00e1tima Bermejo Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Eduardo Alejos Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2024.102418_bib0155","article-title":"Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis","volume":"12","author":"Oba","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semerg.2024.102418_bib0160","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2024.102418_bib0165","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2024.102418_bib0170","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2024.102418_bib0175","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2024.102418_bib0180","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semerg.2024.102418_bib0185","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.chest.2019.03.005","article-title":"Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice","volume":"155","author":"Suissa","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.semerg.2024.102418_bib0190","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/COPD.S347735","article-title":"PRIMUS \u2013 prompt initiation of maintenance therapy in the US: a real-world analysis of clinical and economic outcomes among patients initiating triple therapy following a COPD exacerbation","volume":"17","author":"Tkacz","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semerg.2024.102418_bib0195","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2147\/COPD.S432963","article-title":"Exacerbations and real-world outcomes after single-inhaler triple therapy of budesonide\/glycopyrrolate\/formoterol fumarate. Among patients with COPD: results from the EROS (US) study","volume":"18","author":"Strange","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semerg.2024.102418_bib0200","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2147\/COPD.S370577","article-title":"Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: the INTREPID trial","volume":"17","author":"Halpin","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semerg.2024.102418_bib0205","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2147\/COPD.S398816","article-title":"Real-world treatment patterns and switching following moderate\/severe Chronic Obstructive Pulmonary Disease exacerbation in patients with commercial or Medicare insurance in the United States","volume":"18","author":"Bogart","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semerg.2024.102418_bib0210","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00106-2019","article-title":"Comparative effectiveness of triple therapy versus dual bronchodilation in COPD","volume":"5","author":"Voorham","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.semerg.2024.102418_bib0215","doi-asserted-by":"crossref","first-page":"106398","DOI":"10.1016\/j.rmed.2021.106398","article-title":"TRICOP \u2013 a real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD","volume":"182","author":"Marth","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.semerg.2024.102418_bib0220","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00883-2023","article-title":"Single-inhaler triple versus dual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety","volume":"62","author":"Suissa","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semerg.2024.102418_bib0225","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2147\/COPD.S378486","article-title":"Single-inhaler triple versus dual bronchodilator therapy in COPD: real-world comparative effectiveness and safety","volume":"17","author":"Suissa","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semerg.2024.102418_bib0230","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2147\/COPD.S125616","article-title":"\u201cReal-life\u201d inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD","volume":"12","author":"Vogelmeier","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semerg.2024.102418_bib0235","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/COPD.S286559","article-title":"The impact of fixed triple therapy with beclometasone\/formoterol\/glycopyrronium on health status and adherence in chronic obstructive pulmonary disease (COPD) in an Italian context of real life: the TRITRIAL study protocol","volume":"16","author":"Richeldi","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semerg.2024.102418_bib0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12931-021-01615-0","article-title":"Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study","volume":"22","author":"Magnussen","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.semerg.2024.102418_bib0245","article-title":"Antibiotics for exacerbations of chronic obstructive pulmonary disease","volume":"10","author":"Vollenweider","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semerg.2024.102418_bib0250","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/fampra\/cmac002","article-title":"Acute lower respiratory infections: real-world evidence of antibiotic prescription pattern and costs from a large administrative Italian database","volume":"39","author":"Calabria","year":"2022","journal-title":"Fam Pract"},{"key":"10.1016\/j.semerg.2024.102418_bib0255","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/15412555.2021.2000957","article-title":"Prevalence, pattern, risks factors and consequences of antibiotic resistance in COPD: a systematic review","volume":"18","author":"Smith","year":"2021","journal-title":"COPD"},{"key":"10.1016\/j.semerg.2024.102418_bib0260","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/15412555.2016.1238450","article-title":"The risk of sepsis with inhaled and oral corticosteroids in patients with COPD","volume":"14","author":"Ernst","year":"2017","journal-title":"COPD"},{"key":"10.1016\/j.semerg.2024.102418_bib0265","article-title":"COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67000 patients with COPD followed for 12 months","volume":"6","author":"Sivapalan","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.semerg.2024.102418_bib0270","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12931-023-02311-x","article-title":"In \u2018real world\u2019 patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations","volume":"24","author":"Worth","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.semerg.2024.102418_bib0275","doi-asserted-by":"crossref","first-page":"20","DOI":"10.36469\/001c.55635","article-title":"PROMETHEUS: long-term exacerbation and mortality benefits of implementing single-inhaler triple therapy in the US COPD population","volume":"10","author":"Criner","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.semerg.2024.102418_bib0280","doi-asserted-by":"crossref","DOI":"10.2147\/COPD.S312853","article-title":"Quantifying the economic impact of delayed multiple-inhaler triple therapy initiation in patients with COPD: a retrospective cohort study of linked electronic Medical record and hospital administrative data in England","volume":"16","author":"Sansbury","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semerg.2024.102418_bib0285","doi-asserted-by":"crossref","DOI":"10.1111\/crj.13190","article-title":"Adherence to COPD free triple inhaled therapy in the real world: a primary care based study","author":"Zucchelli","year":"2020","journal-title":"Clin Respir J"},{"key":"10.1016\/j.semerg.2024.102418_bib0290","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2147\/COPD.S290773","article-title":"Real-world treatment patterns of multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in UK general practice","volume":"16","author":"Sansbury","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.semerg.2024.102418_bib0295","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.chest.2022.06.033","article-title":"Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain","volume":"162","author":"Alc\u00e1zar-Navarrete","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.semerg.2024.102418_bib0300","unstructured":"Global strategy for prevention, diagnosis and management of COPD: 2024 Report. Available from: https:\/\/goldcopd.org\/2024-gold-report-2\/ [consulted 1.7.24]."}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359324002284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359324002284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:49:29Z","timestamp":1749185369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359324002284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1138359324002284"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2024.102418","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple inhaled therapy of formoterol\/glycopyrrolate\/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2024.102418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102418"}}